A 58-year-old man with cirrhosis (Child-Pugh B) and a 3.5 cm solitary hepatocellular carcinoma in the right lobe, without vascular invasion or extrahepatic metastases, presents for treatment planning. Which is the drug of choice for systemic therapy if he is not a candidate for curative resection or transplantation?

Explanation

## First-Line Systemic Therapy for Advanced HCC **Key Point:** Atezolizumab + bevacizumab is the preferred first-line systemic regimen for unresectable HCC based on the IMbrave150 trial, which demonstrated superior overall survival (OS) and time to progression (TTP) compared to sorafenib monotherapy. ### Evidence Base The IMbrave150 trial (2020) established atezolizumab (anti-PD-L1 checkpoint inhibitor) + bevacizumab (anti-VEGF monoclonal antibody) as the new standard of care: - **Median OS:** 19.2 months vs. 13.2 months (sorafenib) - **Median TTP:** 6.8 months vs. 4.3 months (sorafenib) - **Objective response rate:** 33.2% vs. 13.7% (sorafenib) ### Mechanism of Action | Drug | Class | Target | Rationale | |------|-------|--------|----------| | Atezolizumab | Monoclonal antibody | PD-L1 checkpoint | Restores anti-tumor T-cell immunity | | Bevacizumab | Monoclonal antibody | VEGF | Inhibits angiogenesis; synergizes with immunotherapy | **Clinical Pearl:** The combination addresses two critical HCC pathways: immune evasion (via PD-L1) and neovascularization (via VEGF), resulting in durable responses and improved survival. ### Patient Eligibility - **Unresectable HCC** (not a candidate for curative surgery/transplant) - **ECOG performance status 0–1** - **Child-Pugh A or B** (this patient is Child-Pugh B, eligible) - **No prior systemic therapy** (first-line setting) **High-Yield:** Atezolizumab + bevacizumab has replaced sorafenib as the preferred first-line regimen in major guidelines (ASCO, ESMO, AASLD) since 2020. ### Why Not Other Options? - **Sorafenib:** Historical first-line (SHARP trial, 2008); now second-line after atezolizumab + bevacizumab failure - **Lenvatinib:** Approved as first-line (REFLECT trial, 2018) with OS comparable to sorafenib; used if atezolizumab + bevacizumab contraindicated - **Doxorubicin:** Systemic chemotherapy with poor efficacy in HCC; not standard of care **Warning:** Do not confuse the older paradigm (sorafenib as first-line) with current practice; the 2020 IMbrave150 data shifted the standard.